Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Outcome Measures in Clinical Trials for Multiple Sclerosis.

van Munster CE, Uitdehaag BM.

CNS Drugs. 2017 Mar;31(3):217-236. doi: 10.1007/s40263-017-0412-5. Review.

2.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660.

3.

Imag(in)ing multiple sclerosis: Time to take better pictures.

Reich DS.

J Neuroimmunol. 2017 Mar 15;304:72-80. doi: 10.1016/j.jneuroim.2016.09.015.

PMID:
27742080
4.

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

Huss AM, Halbgebauer S, Öckl P, Trebst C, Spreer A, Borisow N, Harrer A, Brecht I, Balint B, Stich O, Schlegel S, Retzlaff N, Winkelmann A, Roesler R, Lauda F, Yildiz Ö, Voß E, Muche R, Rauer S, Bergh FT, Otto M, Paul F, Wildemann B, Kraus J, Ruprecht K, Stangel M, Buttmann M, Zettl UK, Tumani H.

J Neurol. 2016 Dec;263(12):2499-2504.

5.

Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin.

Sühs KW, Papanagiotou P, Hein K, Pul R, Scholz K, Heesen C, Diem R.

Int J Mol Sci. 2016 Sep 30;17(10). pii: E1666.

6.

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting.

von Gumberz J, Mahmoudi M, Young K, Schippling S, Martin R, Heesen C, Siemonsen S, Stellmann JP.

PeerJ. 2016 Sep 20;4:e2442. doi: 10.7717/peerj.2442.

7.

The topographical model of multiple sclerosis: A dynamic visualization of disease course.

Krieger SC, Cook K, De Nino S, Fletcher M.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e279. doi: 10.1212/NXI.0000000000000279. Review.

8.

A study of patients with aggressive multiple sclerosis at disease onset.

Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon NN, Vartanian T, Perumal JS.

Neuropsychiatr Dis Treat. 2016 Aug 1;12:1907-12. doi: 10.2147/NDT.S111885.

9.

Neurofilament light chain level is a weak risk factor for the development of MS.

Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M.

Neurology. 2016 Sep 13;87(11):1076-84. doi: 10.1212/WNL.0000000000003085. Erratum in: Neurology. 2016 Nov 8;87(19):2068.

10.

Should the symptomatic region be included in dissemination in space in MRI criteria for MS?

Brownlee WJ, Swanton JK, Miszkiel KA, Miller DH, Ciccarelli O.

Neurology. 2016 Aug 16;87(7):680-3. doi: 10.1212/WNL.0000000000002975.

PMID:
27421541
11.

Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome.

Pavelek Z, Vyšata O, Tambor V, Pimková K, Vu DL, Kuča K, Šťourač P, Vališ M.

Biomed Rep. 2016 Jul;5(1):35-40.

12.

Slowly eroding lesions in multiple sclerosis.

Sethi V, Nair G, Absinta M, Sati P, Venkataraman A, Ohayon J, Wu T, Yang K, Shea C, Dewey BE, Cortese IC, Reich DS.

Mult Scler. 2017 Mar;23(3):464-472. doi: 10.1177/1352458516655403.

PMID:
27339071
13.

Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis.

Giffroy X, Maes N, Albert A, Maquet P, Crielaard JM, Dive D.

BMC Neurol. 2016 Jun 1;16:83. doi: 10.1186/s12883-016-0608-1.

14.

Structural Brain Network Characteristics Can Differentiate CIS from Early RRMS.

Muthuraman M, Fleischer V, Kolber P, Luessi F, Zipp F, Groppa S.

Front Neurosci. 2016 Feb 2;10:14. doi: 10.3389/fnins.2016.00014.

15.

Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.

Kosa P, Komori M, Waters R, Wu T, Cortese I, Ohayon J, Fenton K, Cherup J, Gedeon T, Bielekova B.

Mult Scler Relat Disord. 2015 Nov;4(6):526-35. doi: 10.1016/j.msard.2015.08.009.

16.

Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.

Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, Oh J, Reich DS, Richert N, Rammohan K, Khan O, Radue EW, Ford C, Halper J, Li D.

AJNR Am J Neuroradiol. 2016 Mar;37(3):394-401. doi: 10.3174/ajnr.A4539.

17.

Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.

Farber RS, Sand IK.

Ther Adv Neurol Disord. 2015 Sep;8(5):212-32. doi: 10.1177/1756285615598910. Review.

18.

Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis.

Borràs E, Cantó E, Choi M, Maria Villar L, Álvarez-Cermeño JC, Chiva C, Montalban X, Vitek O, Comabella M, Sabidó E.

Mol Cell Proteomics. 2016 Jan;15(1):318-28. doi: 10.1074/mcp.M115.053256.

19.

Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis.

Matthews L, Kolind S, Brazier A, Leite MI, Brooks J, Traboulsee A, Jenkinson M, Johansen-Berg H, Palace J.

PLoS One. 2015 Sep 18;10(9):e0137715. doi: 10.1371/journal.pone.0137715.

20.

CCL27: Novel Cytokine with Potential Role in Pathogenesis of Multiple Sclerosis.

Khaiboullina SF, Gumerova AR, Khafizova IF, Martynova EV, Lombardi VC, Bellusci S, Rizvanov AA.

Biomed Res Int. 2015;2015:189638. doi: 10.1155/2015/189638.

Supplemental Content

Support Center